PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsiron overload
MeSH D019190 - iron overload
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D019189:Iron metabolism disorders
0 Companies
0 Drugs
Success rate
D019190: 
Iron overload
26 Companies
2 Drugs
$
Success rate
D006432:Hemochromatosis
6 Companies
1 Drug
$
Success rate
D006486:Hemosiderosis
21 Companies
1 Drug
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaDeferasirox Deferasirox  2022-09-23   
Taro PharmaceuticalDeferiprone Deferiprone  2019-02-08   
MylanDeferasirox Deferasirox Mylan  2019-09-26   
Deferasirox Deferasirox  2024-03-22   
CiplaDeferasirox Deferasirox  2020-02-11   
NovartisDeferasirox Exjade  2005-11-02 $647 M Q2/19-Q2/22 
Deferasirox Jadenu 2034-11-21 2015-03-30   
Zydus TherapeuticsDeferasirox Deferasirox  2020-05-05   
Sun Pharmaceutical IndustriesDeferasirox Deferasirox  2019-11-20   
Alembic PharmaceuticalsDeferasirox Deferasirox  2019-11-20   
Alkem LaboratoriesDeferasirox Deferasirox  2019-11-20   
Jerome Stevens PharmaceuticalsDeferasirox Deferasirox  2019-12-27   
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
67%
2/3
Phase 2
100%
4/4
Phase 3
57%
8/14
Approved: 4Overall Success rate: 38%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Novartis
Deferasirox,
Alfacalcidol,
Aspartame,
Nepidermin,
Endocrine,
Histone-arginine methyltransferase carm1
Chiesi Farmaceutici
Deferiprone,
Aspartame
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use